Gainers
- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
- COMSovereign Holding Corp. (NASDAQ:COMS) gained 60.4% to close at $0.2484.
- Brickell Biotech, Inc. (NASDAQ:BBI) rose 47.6% to close at $0.1720.
- Decibel Therapeutics, Inc. (NASDAQ:DBTX) gained 44.2% to settle at $3.82 on Wednesday on continued strength after the company on Tuesday reported top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020.
- Aeterna Zentaris Inc. (NASDAQ:AEZS) shares surged 40% to settle at $0.2528.
- Aditxt, Inc. (NASDAQ:ADTX) gained 39.8% to settle at $0.20.
- PARTS iD, Inc. (NYSE:ID) jumped 38.2% to close at $1.41. PARTS iD, last month, posted a Q1 loss of $0.12 per share.
- Avenue Therapeutics, Inc. (NASDAQ:ATXI) gained 32% to close at $0.3235.
- Grove Collaborative Holdings, Inc. (NYSE:GROV) surged 29.5% to settle at $6.11.
- 9F Inc. (NASDAQ:JFU) gained 28% to settle at $1.02.
- Revelation Biosciences, Inc. (NASDAQ:REVB) shares jumped 27.1% to close at $0.6257. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
- Cognition Therapeutics, Inc. (NASDAQ:CGTX) surged 2 7.1% to close at $2.1601. Cognition Therapeutics recently dosed first patient in the SHIMMER study of lead drug CT1812, an experimental, orally delivered small molecule therapeutic intended to address the underlying biology of dementia with Lewy bodies (DLB).
- Fresh Vine Wine, Inc. (NYSE:VINE) gained 26.7% to close at $1.90.
- Integrated Media Technology Limited (NASDAQ:IMTE) shares climbed 24.6% to close at $3.60.
- Hyperfine, Inc. (NASDAQ:HYPR) gained 24.4% to settle at $2.70. Hyperfine named Scott Huennekens as Interim President & CEO.
- Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares gained 21.3% to close at $2.45 after the company announced positive results from its Phase 2b/3 PRISM trial of Haduvio in treating prurigo nodularis, a chronic disease characterized by severe pruritus and the presence of nodules, lesions, and excoriations.
- Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) gained 19.4% to close at $0.5015.
- Enveric Biosciences, Inc. (NASDAQ:ENVB) climbed 18.8% to close at $0.2370.
- Scienjoy Holding Corporation (NASDAQ:SJ) gained 18.4% to settle at $3.35. Scienjoy recently entered into agreements to obtain business controls of operation in Hangzhou to facilitate its business expansion.
- Rain Therapeutics Inc. (NASDAQ:RAIN) surged 17.6% to close at $4.94. JonesTrading recently initiated coverage on the stock with a Buy rating and announced a $17 price target.
- 2U, Inc. (NASDAQ:TWOU) jumped 17.4% to close at $10.92. Indian online education provider Byju’s offered to buy 2U for $15 a share in cash, valuing the edtech company at more than $1 billion, reported Bloomberg, citing a person familiar with the matter.
- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) jumped 17.9% to close at $0.99. HTG Molecular Diagnostics highlighted a publication in Frontiers Medicine.
- Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ:BHAT) gained 16.9% to close at $2.98.
- BRC Inc. (NYSE:BRCC) gained 16.4% to close at $8.93.
- Atara Biotherapeutics, Inc. (NASDAQ:ATRA) surged 15.7% to settle at $7.58.
- Can-Fite BioPharma Ltd. (NYSE:CANF) jumped 15.6% to close at $1.02 as the company announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
- G Medical Innovations Holdings Ltd (NASDAQ:GMVD) shares jumped 15.5% to close at $0.6099.
- Volcon, Inc. (NASDAQ:VLCN) gained 14.2% to close at $1.45.
- Iterum Therapeutics plc (NASDAQ:ITRM) climbed 13.4% to close at $0.2211.
- Catalyst Biosciences, Inc. (NASDAQ:CBIO) gained 13.3% to close at $1.71. Catalyst Biosciences announced plan to distribute cash to stockholders.
- AdTheorent Holding Company, Inc. (NASDAQ:ADTH) surged 11.2% to close at $2.78.
- Agenus Inc. (NASDAQ:AGEN) gained 10.9% to close at $2.04. Agenus announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer.
- Athersys, Inc. (NASDAQ:ATHX) rose 9.2% to close at $0.2861.
- Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares climbed 8.6% to close at $0.3803.
- Beyond Air, Inc. (NASDAQ:XAIR) gained 8.1% to close at $6.25 after the company posted a narrower FY22 loss. The FDA also approved Beyond Air’s LungFit PH to treat term and near-term neonates with hypoxic respiratory failure (often referred to as persistent pulmonary hypertension of the newborn or PPHN).
- Akouos, Inc. (NASDAQ:AKUS) gained 6.3% to close at $5.20.
- LiveOne, Inc. (NASDAQ:LVO) rose 5.3% to settle at $0.80 after reporting better-than-expected Q4 results.
